相关实验视频

Updated: Jan 16, 2026

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

m6A阅读器IGF2BP2通过FOXM1mRNA稳定介导食道状细胞癌中帕克利塔塞尔耐药性

Shiheng Ren¹, Jingru Wu¹, Lening Zhang²

¹Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R. China.

Oncology reports

|October 3, 2025

概括

胰岛素样生长因子2mRNA结合蛋白2 (IGF2BP2) 通过稳定Forkhead box M1 (FOXM1) mRNA,促进食道状细胞癌 (ESCC) 的帕克利塔塞尔耐药性和无氧糖解. 针对这种途径可能会改善ESCC治疗.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

食道状细胞癌 (ESCC) 是中国癌症死亡的主要原因.
帕克利塔克塞尔耐药性和增强的无氧糖解是ESCC治疗的关键挑战.
胰岛素样生长因子2 mRNA结合蛋白2 (IGF2BP2) 调节RNA稳定性,但其在ESCC中的作用尚不清楚.

研究的目的:

研究IGF2BP2在ESCC中介于帕克利塔塞尔耐药性和无氧糖解中的作用和机制.
为了阐明IGF2BP2,叉头盒M1 (FOXM1) 和ESCC细胞中的这些过程之间的关系.

主要方法:

使用ESCC细胞系 (KYSE30,KYSE150) 进行功能实验.
评估了细胞增殖,克隆生成能力,亡和厌氧糖解率.
分析了FOXM1的mRNA稳定性,蛋白质水平,并进行了RNA/m6A测序.
采用生物信息学分析和基因沉默/过度表达技术.

主要成果:

生物信息学揭示了IGF2BP2在ESCC中的过度表达.
抑制IGF2BP2抑制了增殖,克隆原性活性和帕克利塔塞尔耐药性.
抑制IGF2BP2降低了FOXM1mRNA的稳定性和厌氧糖解.
过度表达FOXM1可以抵消IGF2BP2沉默的作用.

结论:

在ESCC中,IGF2BP2-FOXM1信号通路对于调节无氧糖解和帕克利塔塞尔耐药性至关重要.
这一途径代表了改善ESCC治疗结果的潜在治疗目标.

关键词:

叉头盒 M1 叉头盒无氧糖溶解是一种无氧糖溶解.食管状细胞癌的癌症类似胰岛素的生长因子2 mRNA结合蛋白2 2 帕克利塔克塞尔耐药性已经出现.

更多相关视频

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...